Afatinib-related nonhematologic adverse events: is common evaluation enough for now?
- PMID: 24493732
- DOI: 10.1200/JCO.2013.52.4538
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?
Comment in
-
Reply to F. De Marinis et al.J Clin Oncol. 2014 Mar 10;32(8):865. doi: 10.1200/JCO.2013.54.1904. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493733 No abstract available.
Comment on
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1. J Clin Oncol. 2013. PMID: 23816960 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
